𝔖 Bobbio Scriptorium

✦ LIBER ✦

Improvement in Disease-Free Survival with Doxorubicin/Docetaxel/Cyclophosphamide (TAC) Versus 5-Fluorouracil/Doxorubicin/Cyclophosphamide (FAC) as Adjuvant Therapy for Node-Positive Breast Cancer

✍ Scribed by Amy I. D'Orazio; Joyce O'Shaughnessy

Book ID: 117794008
Publisher: CIG Media Group, LP.
Year: 2002
Tongue: English
Weight: 96 KB
Volume: 3
Category: Article
ISSN: 1526-8209
DOI: 10.1016/s1526-8209(11)70170-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost–effectiveness analysis of adjuvant

Cost–effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)

✍ Sang Gyu Lee; Young Geon Jee; Hyun Chul Chung; Sung-Bae Kim; Jungsil Ro; Young-H 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 231 KB

Quality of life and toxicity in breast c

Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil)

✍ N. Hatam; N. Ahmadloo; A. Ahmad Kia Daliri; P. Bastani; M. Askarian 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 178 KB

P180 A cost effectiveness analysis of ad

P180 A cost effectiveness analysis of adjuvant chemotherapy for node positive early breast cancer in South Africa: docetaxel, doxorubicin and cyclophosphamide (TAC) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)

✍ B.L. Rapoport; S.D. Moodley; C. Jacobs; R. Pienaar; S. Fourie; W.M. Szpak 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Adjuvant docetaxel plus doxorubicin and

Adjuvant docetaxel plus doxorubicin and cyclophosphamide increases survival compared with fluorouracil plus doxorubicin and cyclophosphamide in women with operable node-positive breast cancer

✍ Vivek Roy; Edith A. Perez 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 74 KB

PCN12 IMPACT OF ADJUVANT CHEMOTHERAPY WI

PCN12 IMPACT OF ADJUVANT CHEMOTHERAPY WITH DOCETAXEL FOR EARLY BREAST CANCER: COST-EFFECTIVENESS ANALYSIS (CEA) OF A DOCETAXEL, DOXORUBICIN AND CYCLOPHOSPHAMIDE REGIMEN (TAC) VERSUS 5-FLUOROURACIL, DOXORUBICIN AND CYCLOPHOSPHAMIDE (FAC) IN FRANCE

✍ H Miadi-Fargier; C Le Pen; MC Woronoff-Lemsi; JP Guastalla; X Pivot; H Roché; F 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Doxorubicin and cyclophosphamide adjuvan

Doxorubicin and cyclophosphamide adjuvant chemotherapy is no more effective than cyclophosphamide, methotrexate, and 5-fluorouracil for premenopausal axillary lymph node positive breast cancer: There is no clear evidence that HER-2 status affects the relative effects of doxorubicin and cyclophosphamide vs cyclophosphamide, methotrexate and 5-fluorouracil in women with operable breast cancer

✍ Dino Amadori 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 346 KB